The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’s Substack by Magnus Ofstad. In this ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

In a report released yesterday, Mohit Bansal from Wells Fargo assigned a Hold rating on Merck & Company (MRK – Research Report), ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.